Here is the design of a clinical trial:

Official Title: Scheme Optimization of Acupoints Compatibility and Influence Factors of the Effect

Included conditions:
- Primary Insomnia

Study Armgroups:
- {'label': 'Single point group (Shenmen)', 'type': 'OTHER', 'description': 'Patients will be acupuncture with Shenmen(HT7).', 'interventionNames': ['Other: acupuncture']}
- {'label': 'Sancai coordinated points group', 'type': 'OTHER', 'description': 'Patients in Sancai coordinated points group, will be acupuncture with Baihui(DU20), Shenmen(HT7), Sanyinjiao(SP6).', 'interventionNames': ['Other: acupuncture']}
- {'label': 'Control group', 'type': 'OTHER', 'description': 'Patients in Control group, will be acupuncture with at the junction of deltoid and biceps.', 'interventionNames': ['Other: acupuncture']}

Interventions:
- {'type': 'OTHER', 'name': 'acupuncture', 'description': 'Patients will be treated with Shenmen(HT7), needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.', 'armGroupLabels': ['Single point group (Shenmen)']}
- {'type': 'OTHER', 'name': 'acupuncture', 'description': 'Patients in Sancai coordinated points group, will be treated with Baihui(DU20), Shenmen(HT7), Sanyinjiao(SP6), needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.', 'armGroupLabels': ['Sancai coordinated points group']}
- {'type': 'OTHER', 'name': 'acupuncture', 'description': 'Patients in Control group, will be treated with at the junction of deltoid and biceps, needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.', 'armGroupLabels': ['Control group']}

Primary Outcomes:
- {'measure': 'Pittsburgh sleep quality index(PSQI)', 'timeFrame': '9 weeks'}

Please estimate the sample size based on the assumption: 
Significance level (α) = 0.05, Power = 90%, Dropout rate = 20%
2.8
        Sample size
        A power analysis is calculated before conducting this trial, which Î±â=â0.05 and powerâ=â90%. According to the previous pilot study, percentages of responders for the primary endpoint are verum 87.5%, sham 25%. Therefore, the sample size in this trial can be estimated initially according to the following formula. Each group needs at least 111 patients (assuming a 20% dropout rate), 333 patients in 3 groups totally will be enrolled in the study.
        
n=2(uÎ±'+uÎ²)2p(1âp)(p1âp2)2